pasritamig, KLK2 T-cell engager, bispecific antibody prostate cancer, Phase I trial results, mCRPC immunotherapy, Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study with Capucine ...

The prevalence of kidney stone disease and associated events is rising, with modern surgical approaches emphasizing minimally invasive techniques like ambulatory percutaneous nephrolithotomy (PCNL).

Neeraj Agarwal is joined by Zeynep Ozay to discuss a comparative effectiveness study of lutetium-177 versus cabazitaxel in metastatic castration-resistant prostate cancer. Using the nationwide ...

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

Neeraj Agarwal speaks with Praful Ravi about an individual patient data meta-analysis examining docetaxel addition to ADT plus radiation therapy in high-risk localized prostate cancer. The ISECaP ...

PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...

Zachary Klaassen discusses the NureCombo Trial with Chiara Mercinelli, examining neoadjuvant therapy for muscle-invasive bladder cancer. This phase II trial investigated nab-paclitaxel plus nivolumab ...

Looking for the latest abstracts on prostate cancer treatment and research? We've got you covered and then some.

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Peyronie's Disease - Read the latest Peyronie's Disease research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Bladder Research - Read the latest Bladder Research research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.